[G22-03] Tofacitinib (rheumatoid arthritis) - Addendum to Commission A21-115
Last updated 17.02.2022
Project no.:
G22-03
Commission:
Commission awarded on 11.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Immune system and infections
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
Federal Joint Committee (G-BA)
2022-02-17 A G-BA decision was published.